Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Companion Dx Draft Guidance: Broad In Scope, Limited In Detail

This article was originally published in The Gray Sheet

Executive Summary

FDA's draft guidance on the development of companion diagnostics for drug therapies, released July 12, delivers on a promise to publicly outline how it will address review of those products, but at only 12 pages, it has left some in industry longing for more insight.
Advertisement

Related Content

FDA To Companion Dx Developers: Pre-Trial Assay Validation Is Key
Team Work: Pfizer, Abbott Gain Swift Approvals For Lung Cancer Drug/Test Combo
Regulatory News In Brief
News In Brief
The Personalized Medicine Middle: Coalition Sends Consensus Concepts To Hill
News In Brief
Personalized Medicine Expert Gains Prominent FDA Role In Agency Reorg
FDA: Draft Guidance For Laboratory-Developed Test Regs Taking Extra Time
Industry Seeks Changes In FDA Drug/Diagnostic Co-Development Model
Industry Seeks Changes In FDA Drug/Diagnostic Co-Development Model

Topics

Advertisement
UsernamePublicRestriction

Register

MT030341

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel